Interestingly, Tao et al. provide additional knowledge about the mechanism of action underlying the antivisceral obesity effect of apigenin; here, the authors found that apigenin can counteract metabolic syndrome by decreasing the visceral obesity via inhibiting CD36 and STAT3 signals and consequently reducing PPARγ expression in adipocytes [175]. Here, CD36 is linked to obesity disorder.